Adaptive biotechnologies stock.
Get the latest Adaptive Biotechnologies Corporation (ADPT) stock quote, history, news and other vital information to help you with your stock trading and investing. See the performance outlook, earnings date, dividend yield, research reports and more for ADPT on NasdaqGS.
Jun 30, 2022 · SEATTLE, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended ... Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2023 Earnings Call Transcript November 9, 2023 Adaptive Biotechnologies Corporation misses on earnings expectations. Reported EPS is $-0.35 ...0.86%. $864.11M. ADPT | Complete Adaptive Biotechnologies Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Adaptive Biotechnologies CEO on the company’s IPO and pipeline. Adaptive has agreed to spend a minimum of $12 million on Azure over seven years, according to its IPO prospectus, and Microsoft is ...
View Adaptive Biotechnologies Corporation ADPT investment & stock information. Get the latest Adaptive Biotechnologies Corporation ADPT detailed stock ...Piper Sandler has a $15 target price on Adaptive Biotechnologies stock. The consensus target is $12.29, and shares last traded on Friday at $8.39. ALSO READ: 5 Warren Buffett Dividend Stocks to ...
Adaptive’s net loss came in at $50.3 million, compared to $45.3 million in the same period last year. The company’s stock dipped nearly 5% today. Adaptive Biotechnologies hired Goldman Sachs ...
SEATTLE, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth …Mar 31, 2023 · As of March 31, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.83. Adaptive Biotechnologies Corp is up 4.87% from its previous closing price of $8.42. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $8.21 and $8.67. Currently, there are 143.06 million shares of Adaptive ... SEATTLE, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the pricing of its underwritten public …... shares and is commonly used to measure how much a company is worth. Market cap history of Adaptive Biotechnologies from 2019 to 2023. 2020 2021 2022 2023 $2B ...Nov 29, 2023 · Stock analysis for Adaptive Biotechnologies Corp (ADPT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
One biotechnology topic is the genetic modification of crops. There are also a variety of biotech companies that are coming out with treatments for patients dealing with major illnesses such as breast cancer. There are even attempts to deve...
SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it has entered into a translational collaboration with Takeda to …
April 18, 2023 at 12:10 PM · 3 min read. You may think that with a price-to-sales (or "P/S") ratio of 6.4x Adaptive Biotechnologies Corporation ( NASDAQ:ADPT) is a stock to potentially avoid ...SEATTLE, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global translational collaboration with BeiGene to assess ...This presentation has been prepared by Adaptive Biotechnologies Corporation (“we,” “us,” “our,” “Adaptive” or the “Company”) and is made for informational purposes only. The information set forth herein does not purport to be complete or …According to the Biotechnology Industry Organization, there are more than 250 biotechnology products available, including medicines, vaccines, fertilizers, pest-resistant crops, bio-fuels and bio-defense products.Adaptive Biotechnologies (ADPT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look ...
As of March 24, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.43. Adaptive Biotechnologies Corp is up 7.53% from its previous closing price of $7.84. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $7.79 and $8.24. Currently, there are 143.06 million shares of Adaptive ...Get the latest Adaptive Biotechnologies Corporation (ADPT) stock news and headlines to help you in your trading and investing decisions. ... Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 ...Nov 7, 2023 · SEATTLE, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global translational collaboration with BeiGene to assess ... Stock analysis for Adaptive Biotechnologies Corp (ADPT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2023 Earnings Call Transcript November 9, 2023 Adaptive Biotechnologies Corporation misses on earnings expectations. Reported EPS is $-0.35 ...
Mar 31, 2023 · Revenue was $37.6 million for the quarter ended March 31, 2023, representing a 3% decrease from the first quarter in the prior year. Immune Medicine revenue was $16.2 million for the quarter, representing a 22% decrease from the first quarter in the prior year mainly driven by a decline in amortization of the Genentech upfront payment. The average twelve-month price prediction for Adaptive Biotechnologies is $9.50 with a high price target of $15.00 and a low price target of $6.00. Learn more on ADPT's analyst rating history. Do Wall Street analysts like Adaptive Biotechnologies more than its competitors? Analysts like Adaptive Biotechnologies less than other Medical companies.
Adaptive Biotechnologies CEO on the company’s IPO and pipeline. Adaptive has agreed to spend a minimum of $12 million on Azure over seven years, according to its IPO prospectus, and Microsoft is ...The Investor Relations website contains information about Adaptive Biotechnologies's business for stockholders, potential investors, and financial analysts.Adaptive Biotechnologies Corporation published this content on 10 January 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 10 January 2022 20:27:03 UTC .Adaptive Biotechnologies. Wood has bought almost 10 million shares of this stock for her ARK Genomic Revolution fund. Adaptive Biotechnologies Corp. ( NASDAQ: ADPT ) is a commercial-stage company ...In addition, Adaptive Biotechnologies Corporation has a VGM Score of F (this is a weighted average of the individual Style Scores which allow you to focus on the stocks that best fit your personal ...Stock Price Forecast. The 6 analysts offering 12-month price forecasts for Adaptive Biotechnologies Corp have a median target of 10.00, with a high estimate of 11.00 and a low estimate of 6.00 ...
Analyst Recommendations on Adaptive Biotechnologies Corporation. Morgan Stanley Cuts Adaptive Biotechnologies' Price Target to $10 From $13, Keeps Equalweight …
Description. Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to …
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 24.32% and 1.17%, ... Do the numbers hold clues to what lies ahead for the stock? Skip to main content.Valuation metrics show that Adaptive Biotechnologies Corporation may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth ...About Adaptive Biotechnologies Stock. Adaptive Biotechnologies aims to help scientists look at the immune system in a new way, with a combination of DNA sequencing and high-powered computation, to analyze the DNA sequences that make up the immune system. Unlike other cell types, which operate on a fixed set of code from the human genome, immune ... Stock analysis for Adaptive Biotechnologies Corp (ADPT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Find the latest Adaptive Biotechnologies Corporation (ADPT) stock quote, history, news and other vital information to help you with your stock trading and investing.Stock analysis for Adaptive Biotechnologies Corp (ADPT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA. Insider Trading. Relationship. Date.Aug 2, 2023 · SEATTLE, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ... SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it has entered into a translational collaboration with Takeda to …
SEATTLE, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global translational collaboration with BeiGene to …On June 2, David Westenberg at Piper Sandler initiated coverage on Adaptive Biotechnologies Corporation (NASDAQ:ADPT) stock with a Neutral rating and a target price of $7.50.The Adaptive Biotechnologies stock prediction for 2025 is currently $ 3.58, assuming that Adaptive Biotechnologies shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a -19.24% increase in the ADPT stock price. Instagram:https://instagram. government tax yield investmentticker aggbest bank for financial planningarcteryx used Adaptive Biotechnologies presently has a consensus target price of $9.50, suggesting a potential upside of 102.13%. Immatics has a consensus target price of $17.67, suggesting a potential upside of 96.08%. Given Adaptive Biotechnologies' higher possible upside, analysts plainly believe Adaptive Biotechnologies is more favorable than Immatics. valuable quarters listijr expense ratio Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic … value mercury dime Adaptive Biotechnologies Corporation (ADPT.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Adaptive Biotechnologies ...Earlier this year, an enthusiastic market more than doubled the price of Adaptive Biotechnologies stock. Now that shares are trading around 22% below their recent peak, investors are wondering if ...